DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

Continuous glucose monitoring, compared with fingerstick tests, was feasible and accurate in an inpatient setting among patients and nurses.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Tandem Diabetes TNDM is gaining from continued product innovations. Yet, ongoing macroeconomic challenges and tough ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, today announced the Dexcom G6 Continuous Glucose Monitoring (CGM) System is being ...

Real-world data showed reductions in healthcare resource utilization and improved glycemic control over 1 year with ...

Stock analysis is all about predictions – but as wits from Mark Twain to Yogi Berra have reminded us, predictions are hard, ...

DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, in ...

These once-sizable artificial intelligence (AI) holdings for Google parent Alphabet have been paired down big-time over the ...

Brown, Dexcom Head of Market Access discusses diabetes management. The views expressed here are not necessarily those of The Scotsman and it is recommended to always seek NHS advice before commencing ...

Tandem Diabetes Care, Inc.’s TNDM flagship t:slim X2 insulin pump with Control-IQ automated insulin delivery (AID) technology is now certified for use with Eli Lilly and Company’s LLY Lyumjev (insulin ...